PE09542015A1 - Domain proteins fibronectin-based support that bind myostatin - Google Patents

Domain proteins fibronectin-based support that bind myostatin

Info

Publication number
PE09542015A1
PE09542015A1 PE2015000354A PE0003542015A PE09542015A1 PE 09542015 A1 PE09542015 A1 PE 09542015A1 PE 2015000354 A PE2015000354 A PE 2015000354A PE 0003542015 A PE0003542015 A PE 0003542015A PE 09542015 A1 PE09542015 A1 PE 09542015A1
Authority
PE
Peru
Prior art keywords
proteins
based support
domain proteins
invention
bind myostatin
Prior art date
Application number
PE2015000354A
Other languages
Spanish (es)
Inventor
Sharon Cload
Linda Engle
Dasa Lipovsek
Malavi Madireddi
Ginger Chao Rakestraw
Joanna Swain
Wenjun Zhao
Martin J Corbett
Alexander T Kozhich
Jr Stanley Richard Krystek
Vidhyashankar Ramamurthy
Hui Wei
Aaron P Yamniuk
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261700697P priority Critical
Priority to US201361780005P priority
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of PE09542015A1 publication Critical patent/PE09542015A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79Transferrins, e.g. lactoferrins, ovotransferrins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

Referida a proteinas del dominio de soporte basadas en fibronectina que se fijan a miostatina. Referring to domain proteins based support fibronectin that bind to myostatin. La invencion tambien se refiere al uso de estas proteinas en aplicaciones terapeuticas para tratar enfermedades de atrofia muscular progresiva y trastornos metabolicos. The invention also relates to the use of these proteins in therapeutic applications to treat muscle wasting diseases and metabolic disorders. La invencion tambien se refiere a celulas que comprenden esas proteinas, polinucleotidos que codifican esas proteinas o fragmentos de estas, ya vectores que comprenden los polinucleotidos que codifican las proteinas de la invencion The invention also relates to cells comprising such proteins, polynucleotides encoding these proteins or fragments thereof, and vectors comprising the polynucleotides encoding the proteins of the invention
PE2015000354A 2012-09-13 2013-09-12 Domain proteins fibronectin-based support that bind myostatin PE09542015A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201261700697P true 2012-09-13 2012-09-13
US201361780005P true 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
PE09542015A1 true PE09542015A1 (en) 2015-06-20

Family

ID=49253416

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000354A PE09542015A1 (en) 2012-09-13 2013-09-12 Domain proteins fibronectin-based support that bind myostatin

Country Status (27)

Country Link
US (7) US8853154B2 (en)
EP (1) EP2895503B1 (en)
JP (2) JP6346895B2 (en)
KR (1) KR20150054938A (en)
CN (2) CN108409856A (en)
AU (2) AU2013315482B2 (en)
BR (1) BR112015005466A2 (en)
CA (1) CA2884730A1 (en)
CL (1) CL2015000500A1 (en)
DK (1) DK2895503T3 (en)
EA (1) EA201590543A1 (en)
HK (1) HK1212717A1 (en)
HR (1) HRP20190845T1 (en)
HU (1) HUE043482T2 (en)
IL (1) IL237559D0 (en)
LT (1) LT2895503T (en)
MX (1) MX2015002894A (en)
NZ (1) NZ628446A (en)
PE (1) PE09542015A1 (en)
PH (1) PH12015500397A1 (en)
RS (1) RS58801B1 (en)
SG (2) SG10201701970TA (en)
SI (1) SI2895503T1 (en)
TN (1) TN2015000086A1 (en)
TW (2) TWI633117B (en)
UY (1) UY35027A (en)
WO (1) WO2014043344A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150133A2 (en) * 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
RS55609B1 (en) 2011-04-13 2017-06-30 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US8853154B2 (en) 2012-09-13 2014-10-07 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
CA2898121A1 (en) 2013-01-25 2014-07-31 Shire Human Genetic Therapies, Inc. Follistatin in treating duchenne muscular dystrophy
ES2645634T3 (en) 2013-02-12 2017-12-07 Bristol-Myers Squibb Company High pH protein refolding methods
WO2014182676A2 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
CA2943228A1 (en) 2014-03-20 2015-09-24 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
WO2015161108A1 (en) * 2014-04-16 2015-10-22 The Scripps Research Institute Pparg modulators for treatment of osteoporosis
WO2016023036A1 (en) * 2014-08-08 2016-02-11 The Regents Of The University Of California High density peptide polymers
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
UY36404A (en) 2014-11-21 2016-06-01 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Monoclonal antibodies (Ab) AS DETECTORS AND INHIBITORS CD73 enzyme activity, and compositions containing them
CN107406494A (en) 2014-11-25 2017-11-28 百时美施贵宝公司 Novel PD-L1 binding polypeptides for imaging
EP3303396A1 (en) 2015-05-29 2018-04-11 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
BR112017028353A2 (en) 2015-06-29 2018-09-04 Squibb Bristol Myers Co cd40 antibodies with enhanced agonist activity
US20180228925A1 (en) * 2015-08-28 2018-08-16 University Of Massachusetts Quantifying Net Axonal Transport in Motor Neuron Pathologies
KR20180073693A (en) 2015-11-09 2018-07-02 브리스톨-마이어스 스큅 컴퍼니 How to manipulate the quality attributes of polypeptides produced in CHO cells
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
WO2017151176A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
RU2613420C1 (en) * 2016-04-13 2017-03-16 Сергей Михайлович Юдин RECOMBINANT PROTEIN Mio-HSP, METHOD OF ITS PRODUCTION, INJECTION PREPARATION FOR MUSCLE MASS INCREASE IN FARM ANIMALS, BIRDS AND ANIMALS OF CANIDS, AS WELL AS METHOD OF USING PREPARATION
WO2018105550A1 (en) * 2016-12-05 2018-06-14 大塚製薬株式会社 Amyotrophy inhibiting composition
TW201843173A (en) 2017-04-07 2018-12-16 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
TW201842929A (en) 2017-05-03 2018-12-16 美商必治妥美雅史谷比公司 Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin
WO2018218056A1 (en) 2017-05-25 2018-11-29 Birstol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2019133747A1 (en) 2017-12-27 2019-07-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
WO2019144945A1 (en) * 2018-01-25 2019-08-01 I-Mab Anti-pd-l1 antibody and il-7 fusions

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5641648A (en) 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5770697A (en) 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5792742A (en) 1991-06-14 1998-08-11 New York University Fibrin-binding peptide fragments of fibronectin
WO2002081494A1 (en) 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
WO1994017097A1 (en) 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
US6673534B1 (en) 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
ES2201076T3 (en) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 growth differentiation.
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
CA2278786C (en) 1997-01-21 2010-07-20 The General Hospital Corporation Selection of proteins using rna-protein fusions
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
CA2293632C (en) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
AT340870T (en) 1998-04-03 2006-10-15 Compound Therapeutics Inc Addressable protein arrays
DE69941116D1 (en) 1998-05-06 2009-08-27 Metamorphix Inc G GDF-8
AT439592T (en) 1998-12-10 2009-08-15 Squibb Bristol Myers Co Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1301538B1 (en) 2000-07-11 2015-12-09 Research Corporation Technologies, Inc Artificial antibody polypeptides
AU1325102A (en) 2000-10-16 2002-04-29 Phylos Inc Protein scaffolds for antibody mimics and other binding proteins
US7598352B2 (en) 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
AU2002307146B2 (en) 2001-04-04 2007-02-01 University Of Rochester AlphaNuBeta3 integrin-binding polypeptide monobodies and their use
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AU2003243436A1 (en) 2002-06-06 2003-12-22 Shohei Koide Reconstituted polypeptides
AR047392A1 (en) 2002-10-22 2006-01-18 Wyeth Corp Neutralizing antibodies against GDF 8 and their use for such purposes
US20080220049A1 (en) 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
TW200531979A (en) 2003-12-05 2005-10-01 Compound Therapeutics Inc Inhibitors of type 2 vascular endothelial growth factor receptors
CA2558805C (en) 2004-03-23 2011-09-27 Eli Lilly And Company Anti-myostatin antibodies
WO2005118646A2 (en) 2004-04-26 2005-12-15 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
AU2005294382A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EA015534B1 (en) 2005-04-25 2011-08-30 Пфайзер Инк. Myostatin antibodies and methods for their use
AU2006283725B2 (en) 2005-08-19 2012-02-16 The Trustees Of The University Of Pennsylvania Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
WO2007044411A2 (en) 2005-10-06 2007-04-19 Eli Lilly And Company Anti-myostatin antibodies
BRPI0617345A2 (en) 2005-10-12 2011-07-26 Lilly Co Eli antimiostatina monoclonal antibody composiÇço pharmaceutical, and their use
BRPI0716249A2 (en) 2006-09-05 2013-09-03 Lilly Co Eli antimiostatin antibodies
WO2008031098A1 (en) 2006-09-09 2008-03-13 The University Of Chicago Binary amino acid libraries for fibronectin type iii polypeptide monobodies
MX2009005466A (en) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir.
EP2111228B1 (en) 2007-02-02 2011-07-20 Bristol-Myers Squibb Company 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
JP5591691B2 (en) 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド Compositions and methods for making biologically active fusion proteins
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2009023184A2 (en) 2007-08-10 2009-02-19 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US20100285000A1 (en) 2007-08-20 2010-11-11 Bristol-Myers Squibb Company Use of vegfr-2 inhibitors for treating metastatic cancer
WO2009058379A2 (en) 2007-10-31 2009-05-07 Medimmune, Llc Protein scaffolds
PE11632009A1 (en) 2007-11-01 2009-08-09 Wyeth Corp GDF8 antibodies
US20110034384A1 (en) 2007-11-28 2011-02-10 Bristol-Myers Squibb Company COMBINATION VEGFR2 THERAPY WITH mTOR INHIBITORS
AU2008345674A1 (en) 2007-12-19 2009-07-09 Centocor, Ortho Biotech Inc. Alternative scaffold protein fusions phage display via fusion to pIX of M13 phage
KR20100111283A (en) 2007-12-27 2010-10-14 노파르티스 아게 Improved fibronectin-based binding molecules and their use
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
AU2009213141A1 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
ES2445695T3 (en) 2008-05-02 2014-03-04 Novartis Ag Binding molecules based on improved fibronectin and their uses
AR071874A1 (en) 2008-05-22 2010-07-21 Squibb Bristol Myers Co Frame domain proteins based multivalent fibronectin
WO2010051274A2 (en) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
TWI496582B (en) 2008-11-24 2015-08-21 Squibb Bristol Myers Co Bispecific egfr/igfir binding molecules
AU2009327189B2 (en) 2008-12-16 2012-09-06 Novartis Ag Yeast display systems
UY32341A (en) * 2008-12-19 2010-07-30 Glaxo Group Ltd Novel antigen binding proteins
WO2010093771A1 (en) 2009-02-11 2010-08-19 Bristol-Myers Squibb Company Combination vegfr2 therapy with temozolomide
BRPI1008532A2 (en) 2009-02-12 2018-04-03 Janssen Biotech Inc "fibronectin domain type III framework-based compositions, methods and uses".
US8067201B2 (en) 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
US20120270797A1 (en) 2009-08-13 2012-10-25 Massachusetts Institute Of Technology Engineered proteins including mutant fibronectin domains
EP2494046B1 (en) 2009-10-30 2018-09-12 Novartis AG Universal fibronectin type iii bottom-side binding domain libraries
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
US8961977B2 (en) 2010-02-12 2015-02-24 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
MX2012009050A (en) 2010-02-18 2012-09-07 Squibb Bristol Myers Co Fibronectin based scaffold domain proteins that bind il-23.
KR20130056870A (en) 2010-04-13 2013-05-30 메디뮨 엘엘씨 Fibronectin type iii domain-based multimeric scaffolds
EA201590910A1 (en) * 2010-04-13 2016-05-31 Бристол-Майерс Сквибб Компани Proteins based on a structural fibronectin domain, connecting pcsk9
MX339126B (en) 2010-04-30 2016-05-11 Janssen Biotech Inc Stabilized fibronectin domain compositions, methods and uses.
TW201138808A (en) 2010-05-03 2011-11-16 Squibb Bristol Myers Co Serum albumin binding molecules
AR081221A1 (en) 2010-05-26 2012-07-04 Regeneron Pharma Anti human GDF8
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
KR20130136443A (en) 2010-07-30 2013-12-12 노파르티스 아게 Fibronectin cradle molecules and libraries thereof
CA2808382A1 (en) 2010-08-16 2012-02-23 Amgen Inc. Antibodies that bind myostatin, compositions and methods
JP2014504587A (en) * 2010-12-22 2014-02-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Fibronectin-based scaffold domain protein that binds to IL-23
RS55609B1 (en) 2011-04-13 2017-06-30 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
EP2710382B1 (en) 2011-05-17 2017-10-18 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
EP3540100A1 (en) 2011-09-27 2019-09-18 Janssen Biotech, Inc. Fibronectin tyoe iii repeat based protein scaffolds with alternative binding surfaces
EP3540070A1 (en) 2012-06-11 2019-09-18 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
RU2630634C2 (en) 2012-06-15 2017-09-11 Пфайзер Инк. Improved antibodies gdf-8 antagonists and their use
US8853154B2 (en) 2012-09-13 2014-10-07 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin

Also Published As

Publication number Publication date
US10245302B2 (en) 2019-04-02
SI2895503T1 (en) 2019-08-30
JP2018183138A (en) 2018-11-22
LT2895503T (en) 2019-07-25
US20170088602A1 (en) 2017-03-30
US8933199B2 (en) 2015-01-13
US20150072919A1 (en) 2015-03-12
TWI633117B (en) 2018-08-21
CL2015000500A1 (en) 2015-07-31
AU2013315482B2 (en) 2018-03-15
KR20150054938A (en) 2015-05-20
EP2895503A1 (en) 2015-07-22
NZ628446A (en) 2017-06-30
IL237559D0 (en) 2015-04-30
SG10201701970TA (en) 2017-05-30
TW201416376A (en) 2014-05-01
US9662373B2 (en) 2017-05-30
RS58801B1 (en) 2019-07-31
PH12015500397A1 (en) 2015-04-27
EP2895503B1 (en) 2019-03-27
CN104768969A (en) 2015-07-08
HK1212717A1 (en) 2016-06-17
US20150231211A1 (en) 2015-08-20
US20140105896A1 (en) 2014-04-17
US20170354718A1 (en) 2017-12-14
US8993265B2 (en) 2015-03-31
US10406212B2 (en) 2019-09-10
US9493546B2 (en) 2016-11-15
HRP20190845T1 (en) 2019-08-09
HUE043482T2 (en) 2019-08-28
CN108409856A (en) 2018-08-17
JP6346895B2 (en) 2018-06-20
JP2015530390A (en) 2015-10-15
AU2018201273A1 (en) 2018-03-15
MX2015002894A (en) 2015-06-03
AU2013315482A1 (en) 2015-03-12
WO2014043344A1 (en) 2014-03-20
BR112015005466A2 (en) 2017-08-08
US8853154B2 (en) 2014-10-07
SG11201501741YA (en) 2015-04-29
US20140309163A1 (en) 2014-10-16
TN2015000086A1 (en) 2016-06-29
TW201823269A (en) 2018-07-01
DK2895503T3 (en) 2019-05-27
US20140107020A1 (en) 2014-04-17
EA201590543A1 (en) 2015-06-30
UY35027A (en) 2014-03-31
CA2884730A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
PE07182016A1 (en) FGF21 mutant polypeptides
CR11795A (en) Immunoglobulins Dual variable domain and uses thereof
UY30892A1 (en) Inhibitors of Akt activity
ECSP14013217A (en) 4-imidazopiridazin-1-yl-benzamide and 4-imidazotriazin-1-yl-benzamides as inhibitors of BTK.
CU20120161A7 (en) 5-fluoro-1H-pyrazolopyridine substituted
ECSP12011720A (en) Heterocyclic compounds and uses thereof
UY32965A (en) Immunoglobulins Dual variable domain and uses thereof
UA117072C2 (en) Cd3-binding molecule capable of binding to human cd3 and cd3, non-human
CL2017003496A1 (en) crystalline forms of an inhibitor of Bruton's tyrosine kinase.
GT201400164A (en) Compounds imidazopirrolidinona
CO6680687A2 (en) Immunoglobulins dual variable domain capable of binding yl 1 beta and IL-17, pharmaceutical compositions and conjugates binding protein thereof
UY35973A (en) Antibody molecules bind tim-3 and uses thereof
CO6400232A2 (en) Binding protein to human CGRP receptors
CY1116578T1 (en) INHIBITORS AND USES bromodomain these
DOP2012000055A (en) Immunoglobulins Dual variable domain and uses thereof
UY31861A (en) Dual variable domain immunoglobulin and uses thereof
UY32812A (en) High-affinity human antibodies to human angiopoietin-2.
AR085335A1 (en) Interleukin-2 mutant polypeptides
UY32860A (en) Compounds and compositions as protein kinase inhibitors
CR20140357A (en) Combined antibodies against CSF-1R human therapy and uses thereof
UY32427A (en) pharmaceutical composition, pharmaceutical form, process for their preparation, methods of treatment and uses thereof
CL2012002037A1 (en) Using dual agonist glucagon-glp-1 as inotropic agent in the treatment of heart disease or cardiac dysfunction
CO6670523A2 (en) antibodies specific for fibroblast activation protein (FAP), polynucleotides encoding such antibodies, and vectors and host cells comprising such nucleotide
CY1120177T1 (en) Flagellin roseburia and immunomodulation
UY34454A (en) Binding molecules for bcma and cd3